ERBB2 and breast carcinoma: Although it remains unclear why Her2-negative breast cancer is resistant to Bevacizumab when combined with other chemotherapies, one possibility is that overexpression of other pro-angiogenic/pro-lymphangiogenic growth factors in this cancer type may compensate for inhibition of VEGF-A.